"I have basic trust in you and my integrity as a professional manager. But if the company is all Mr. Lei, then even if I have 90% of the equity in this company, it is not my company."

"I believe you can understand what I mean. I prefer to prepare in advance. The relationship between senior and junior is only in front of the interests, but there is no guarantee. You should know very well how big the endorphin market is."

Zheng Li did not shy away from his purpose and his concerns about the people sent by Cheng Gang and other Lei Jun.

After saying this, Cheng Gang's evaluation of Zheng Li was one level higher. Everything is planned and everything is not planned.

As an 18-year-old young man, it is difficult to maintain a clear mind when he gets the other party’s investment of 50 million yuan.

In addition, Cheng Gang is also very curious about Li Miaomiao. What is the excellence of her when she can entrust Zheng with important tasks?

"I understand your concerns. I will prove my ethics with actions. As long as I am still at Science and Technology Biologics for a day, I will consider its interests."

"Also, Ms. Li, how old are I to you? I usually call you Miaomiao. Do you think it's okay?"

Li Miaomiao replied: "No problem, Brother Cheng."

Cheng Gang thought in his heart that the other party was also a wonderful person and could understand his subtext as soon as possible:

"Miaomiao, let me briefly introduce the structure of our company to you. Now there are only financial departments, human resources departments, legal departments and R&D departments, because our first product is not officially launched yet."

"On the eve of our first drug being approved for marketing, we will form a sales department to be responsible for the sales of the drug. The structure of a Caochuang Biopharma company is roughly this: finance, human resources, sales, legal affairs and R&D."

"Company like PR, clinical trials, quality management, etc. will only be considered for establishment after the company grows."

"We will have our own standardized production base in the future."

"Like Hengrui Medicine, they have their own production bases in many places across the country, and they also have R&D and production bases in Gusu."

"Our company is now headed by Director Zheng, and I am responsible for the R&D department of other departments, but Director Zheng has the right to decide."

"My personal advice is that you will mainly participate in personnel and financial work in the early stage, so that you can have a certainty about the overall situation of the company as soon as possible."

"When you get started with financial and personnel work, you will have an in-depth understanding of the business."

After Cheng Gang finished speaking, Zheng Li nodded slightly. He knew that Cheng Gang's proposal was not his own selfishness.

Li Miaomiao: "Thanks to Brother Cheng for his opinions, I also think it is better to start with personnel and finance first."

Zheng Li made a decision: "Chen Gang, please arrange it, I will continue to work downstairs."

......

Before a new drug is conducted for formal clinical trials, it is necessary to conduct qualitative analysis and preclinical trials, and then obtain approval from the State Food and Drug Administration before human clinical trials can be conducted.

The qualitative analysis of endorphins is relatively simple, because there are previous papers for qualitative analysis, and Science and Technology Biotechnology only needs to write a review.

Preclinical trials are relatively difficult because before patent registration is approved, endorphins cannot be produced in industrial mass and can only be prepared through laboratory methods.

After a month and a half, Science and Technology Biotech completed the preclinical trial work and entered the waiting period for approval to obtain clinical trials.

Endorphins are very special. They are not a complete new drug. They were discovered very early, but they are not a generic drug because no pharmaceutical factory has mass-produced endorphins for sale before.

If it is a generic drug, no clinical trial is required, only bioequivalence trials are required.

Domestic biomedical patent registration is faster than ordinary patent registration, and endorphins are innovative drugs, so the registration process is faster.

After three months, the industrial production method of endorphins has been approved by the national patent, and the results of the first phase clinical trial have also been released.

Phase I clinical trials generally require only 20 to 80 cases, while phase I clinical trials of endorphins were conducted in 100 cases.

Phase I clinical trials verified the efficacy of endorphin injection, proving that its analgesic effect is better than morphine. Among them, in the controlled experiments, it was proved that endorphin can still work in some patients who are resistant to analgesics.

At the same time, the patent registration of endorphins around the world is almost over.

This also led to the fact that Lei Jun's first investment was almost 50 million yuan, and Science and Technology Biotechnology was about to start the second round of investment.

In fact, as early as after the patent was approved, relevant investment institutions had found Cheng Gang and asked to conduct research on the doorstep.

As soon as the first phase of clinical trial report was released, many institutions with great powers had already obtained it.

Investment institutions all believe that this is a business that is stable and profitable, and investment means making money.

At the same time, these investment institutions have once again raised their evaluation of Zheng Li.

There is an insurmountable gap between laboratory products and industrial production, and many laboratory products will take many years to use.

Zheng Li was able to invent the laboratory method of endorphins and simplify the process to achieve industrial mass production. Investment institutions also need to invest in Science and Technology Biotechnology for people.

For a time, investment institutions came one after another.

"Stephanie, you also know that I am just the general manager, and I can't talk about the second round of investment in Science and Technology Biotechnology."

Cheng Gang looked helpless. The recent phone calls have taken up a lot of his energy because many of them are acquaintances and are hard to refuse.

The investment institution could not contact Zheng Li and came to harass him. The person who was talking to him now is the head of the investment department of Goldman Sachs Group in Greater China - stephanie   hui.

"We are really optimistic about the prospects of Sci-tech Biotech and hope to participate in the second round of investment in Sci-tech Biotech Biotech."

"Goldman Sachs can help Kechuang Biotech accelerate the progress of patent applications in Europe and the United States, and can help you complete clinical trials faster and obtain FDA approval."

"Goldman Sachs can help the growth of Sci-Tech Bio in all aspects."

The conditions proposed by stephanie are all urgently needed by science and technology innovation biology now.

Cheng Gang was unmoved, and he smiled bitterly: "Stephanie, I have heard I've heard idg's young, sequoia's tuvia, e, etc. all of you said."

"What you said made me very moved. I am willing to let you participate in the second round of venture capital, but I am not a big boss, I don't even have any shares. I am just a manager."

"I have no right to decide when the second round of investment will be started, when, and which institutions to participate."

"You go and ask Mr. Lei of Dami, he has a say better than me."

Stephanie smiled and said, "It seems that I was disturbing you. I don't need you to give me any affirmative answers, nor do you need to do anything that goes against the interests of your company."
Chapter completed!